Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera

[1]  M. Tuluc,et al.  Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes , 2017, Journal of Immunotherapy for Cancer.

[2]  S. Pitteri,et al.  Parallel Comparison of N-Linked Glycopeptide Enrichment Techniques Reveals Extensive Glycoproteomic Analysis of Plasma Enabled by SAX-ERLIC. , 2017, Journal of proteome research.

[3]  G. Hostetter,et al.  A Gastric Glycoform of MUC5AC Is a Biomarker of Mucinous Cysts of the Pancreas , 2016, PloS one.

[4]  E. White,et al.  Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone * , 2016, The Journal of Biological Chemistry.

[5]  Ian G. Mills,et al.  The role of glycans in the development and progression of prostate cancer , 2016, Nature Reviews Urology.

[6]  P. Rudd,et al.  Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes , 2016, Theranostics.

[7]  Haiying Yu,et al.  Serum CEACAM1 Level Is Associated with Diagnosis and Prognosis in Patients with Osteosarcoma , 2016, PloS one.

[8]  T. Wilt,et al.  PSA Screening for Prostate Cancer: Why Saying No is a High-Value Health Care Choice. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  P. Stattin,et al.  Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune Response in Opposite Directions , 2015, Scientific Reports.

[10]  R. Andersson,et al.  SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer , 2015, Pancreas.

[11]  S. Pinho,et al.  Glycosylation in cancer: mechanisms and clinical implications , 2015, Nature Reviews Cancer.

[12]  M. Fujisawa,et al.  CD-163 correlated with symptoms (pain or discomfort) of prostatic inflammation. , 2015, International journal of clinical and experimental pathology.

[13]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[14]  Jianguo Feng,et al.  SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target. , 2014, Current pharmaceutical design.

[15]  W. Hancock,et al.  Development of an improved fractionation of the human plasma proteome by a combination of abundant proteins depletion and multi-lectin affinity chromatography. , 2014, Bioanalysis.

[16]  B. Mellado,et al.  SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations , 2014, Molecular Cancer.

[17]  T. Habuchi,et al.  Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. , 2014, Biochemical and biophysical research communications.

[18]  Michael J. Barry,et al.  Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. , 2014, JAMA.

[19]  E. Giannoni,et al.  The Role of M1 and M2 Macrophages in Prostate Cancer in relation to Extracapsular Tumor Extension and Biochemical Recurrence after Radical Prostatectomy , 2014, BioMed research international.

[20]  A. Theocharis,et al.  Serglycin: At the Crossroad of Inflammation and Malignancy , 2014, Front. Oncol..

[21]  S. Pitteri,et al.  Performance evaluation of affinity ligands for depletion of abundant plasma proteins. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[22]  N. Taniguchi,et al.  Glycan Biomarker Discovery , 2013, Proteomics. Clinical applications.

[23]  H. Haller,et al.  Zinc-alpha2-glycoprotein in patients with acute and chronic kidney disease , 2013, BMC Nephrology.

[24]  P. Conroy,et al.  Aberrant PSA glycosylation—a sweet predictor of prostate cancer , 2013, Nature Reviews Urology.

[25]  L. R. Ruhaak,et al.  Developments in the Identification of Glycan Biomarkers for the Detection of Cancer , 2013, Molecular & Cellular Proteomics.

[26]  N. Lumen,et al.  Glycosylation of prostate specific antigen and its potential diagnostic applications. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[27]  Pauline M Rudd,et al.  Glycans as cancer biomarkers. , 2012, Biochimica et biophysica acta.

[28]  Jie Chen,et al.  SPARC Is a Key Regulator of Proliferation, Apoptosis and Invasion in Human Ovarian Cancer , 2012, PloS one.

[29]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[30]  S. Hanash,et al.  A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome. , 2011, Analytical chemistry.

[31]  R. Aebersold,et al.  A High-Confidence Human Plasma Proteome Reference Set with Estimated Concentrations in PeptideAtlas* , 2011, Molecular & Cellular Proteomics.

[32]  Jacob Kennedy,et al.  Plasma Proteome Profiles Associated with Inflammation, Angiogenesis, and Cancer , 2011, PloS one.

[33]  Adam Rauch,et al.  LabKey Server: An open source platform for scientific data integration, analysis and collaboration , 2011, BMC Bioinformatics.

[34]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[35]  Ruedi Aebersold,et al.  Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[36]  Pamela A Shaw,et al.  Exact and Asymptotic Weighted Logrank Tests for Interval Censored Data: The interval R package. , 2010, Journal of statistical software.

[37]  Peter C Albertsen,et al.  Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. , 2009, Journal of the National Cancer Institute.

[38]  G. Wiederschain,et al.  Essentials of glycobiology , 2009, Biochemistry (Moscow).

[39]  M. Tang,et al.  SPARC in cancer biology: its role in cancer progression and potential for therapy. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[40]  W. Hancock,et al.  Preparation of a high-performance multi-lectin affinity chromatography (HP-M-LAC) adsorbent for the analysis of human plasma glycoproteins. , 2008, Journal of separation science.

[41]  Robert Burke,et al.  ProteoWizard: open source software for rapid proteomics tools development , 2008, Bioinform..

[42]  S. Hanash,et al.  Mining the plasma proteome for cancer biomarkers , 2008, Nature.

[43]  J. Nickel.  Inflammation and benign prostatic hyperplasia. , 2008, The Urologic clinics of North America.

[44]  J. Marth,et al.  Glycosylation in Cellular Mechanisms of Health and Disease , 2006, Cell.

[45]  Veronika A. Glukhova,et al.  Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. , 2006, Journal of proteome research.

[46]  C. Tsai,et al.  Purification and Characterization , 2006 .

[47]  W. Hancock,et al.  Monitoring glycosylation pattern changes of glycoproteins using multi-lectin affinity chromatography. , 2005, Journal of chromatography. A.

[48]  Robertson Craig,et al.  TANDEM: matching proteins with tandem mass spectra. , 2004, Bioinformatics.

[49]  T. Byzova,et al.  Molecular Pathway for Cancer Metastasis to Bone* , 2003, Journal of Biological Chemistry.

[50]  R. Aebersold,et al.  A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.

[51]  Pauline M Rudd,et al.  Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. , 2003, Glycobiology.

[52]  N. Anderson,et al.  The Human Plasma Proteome: History, Character, and Diagnostic Prospects , 2003, Molecular & Cellular Proteomics.

[53]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[54]  R L Vessella,et al.  Differential expression of osteonectin/SPARC during human prostate cancer progression. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  R Apweiler,et al.  On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. , 1999, Biochimica et biophysica acta.

[56]  T. Stamey,et al.  Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. , 1997, The Journal of urology.

[57]  C. Janeway.  Immunobiology: The Immune System in Health and Disease , 1996 .

[58]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[59]  S. Pitteri,et al.  Multi-Lectin Affinity Chromatography for Separation, Identification, and Quantitation of Intact Protein Glycoforms in Complex Biological Mixtures. , 2017, Methods in molecular biology.

[60]  J. Nyalwidhe,et al.  Altered glycosylation in prostate cancer. , 2015, Advances in cancer research.

[61]  D. Brandeis,et al.  A Review of Current Evidence , 2014 .

[62]  J. Goodwin,et al.  The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.

[63]  Dylan J. Sorensen,et al.  A lectin affinity workflow targeting glycosite-specific, cancer-related carbohydrate structures in trypsin-digested human plasma. , 2011, Analytical biochemistry.

[64]  S. Kaplan,et al.  Role of inflammation in benign prostatic hyperplasia. , 2011, Reviews in urology.

[65]  Adam Rauch,et al.  Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. , 2006, Journal of proteome research.

[66]  N. Anderson,et al.  HISTORY, CHARACTER, AND DIAGNOSTIC PROSPECTS* , 2002 .

[67]  D. Dudley,et al.  The immune system in health and disease. , 1992, Bailliere's clinical obstetrics and gynaecology.

[68]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.